Biosimilar Naming Conventions: Pharmacist Perceptions and Impact on Confidence in Dispensing Biologics.

@article{Tomaszewski2016BiosimilarNC,
  title={Biosimilar Naming Conventions: Pharmacist Perceptions and Impact on Confidence in Dispensing Biologics.},
  author={Daniel J. Tomaszewski},
  journal={Journal of managed care & specialty pharmacy},
  year={2016},
  volume={22 8},
  pages={
          919-26
        }
}
BACKGROUND The approval of the first biosimilar in the United States has placed increased pressure on the FDA to provide guidance on the naming convention that will be assigned to current and future biosimilars. The release of the FDA draft guidance on nonproprietary naming of biosimilars in August 2015 established a naming convention for all biologic products, including biosimilars. However, the draft guidance is nonbinding while the FDA continues to receive input from stakeholders, and it… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-6 OF 6 REFERENCES

and Drug Administration

U. S. Foo
  • How FDA reviews proposed drug names. Available at: http://www.fda.gov/downloads/drugs/drugsafety/medication errors/ucm080867.pdf. Accessed June 17,
  • 2016
VIEW 2 EXCERPTS

First biosimilar approved in US: filgrastim-sndz (Zarxio)

Z. Chustecka
  • Medscape. March
  • 2014
VIEW 1 EXCERPT

Hatch call on Burwell to immediately release guidance on biosimilar drugs

L Wolgemuth, Jeffries JA. Alexander
  • U.S. Senate Committee on Health, Education, Labor and Pensions. August
  • 2014

Similar Papers

Loading similar papers…